EVAXION A/S (EVAX) Stock Price, Forecast & Analysis

NASDAQ:EVAX • US29970R3030

3.29 USD
-0.19 (-5.46%)
Last: Feb 20, 2026, 04:30 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News

EVAX Key Statistics, Chart & Performance

Key Statistics
Market Cap27.44M
Revenue(TTM)7.65M
Net Income(TTM)-11.98M
Shares8.34M
Float6.81M
52 Week High12.15
52 Week Low1.2
Yearly DividendN/A
Dividend Yield0%
EPS(TTM)-4.01
PEN/A
Fwd PEN/A
Earnings (Next)03-05
IPO2021-02-05
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
EVAX short term performance overview.The bars show the price performance of EVAX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 -10 -20 -30

EVAX long term performance overview.The bars show the price performance of EVAX in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 20 -20 -40 -60 -80

The current stock price of EVAX is 3.29 USD. In the past month the price decreased by -21.48%. In the past year, price increased by 31.23%.

EVAXION A/S / EVAX Daily stock chart

EVAX Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating
EVAX Full Technical Analysis Report

EVAX Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to EVAX. EVAX may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
EVAX Full Fundamental Analysis Report

EVAX Financial Highlights

Over the last trailing twelve months EVAX reported a non-GAAP Earnings per Share(EPS) of -4.01. The EPS increased by 45.07% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -53.35%
ROE -192.35%
Debt/Equity 1.73
Chartmill High Growth Momentum
EPS Q2Q%105%
Sales Q2Q%148.33%
EPS 1Y (TTM)45.07%
Revenue 1Y (TTM)132.2%
EVAX financials

EVAX Forecast & Estimates

9 analysts have analysed EVAX and the average price target is 12.58 USD. This implies a price increase of 282.37% is expected in the next year compared to the current price of 3.29.

For the next year, analysts expect an EPS growth of 85.61% and a revenue growth 14.66% for EVAX


Analysts
Analysts82.22
Price Target12.58 (282.37%)
EPS Next Y85.61%
Revenue Next Year14.66%
EVAX Analyst EstimatesEVAX Analyst Ratings

EVAX Ownership

Ownership
Inst Owners1.48%
Ins Owners0.68%
Short Float %1%
Short Ratio0.79
EVAX Ownership

EVAX Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
ABBV ABBVIE INC15.48396.512B
AMGN AMGEN INC16.63202.199B
GILD GILEAD SCIENCES INC16.97187.492B
VRTX VERTEX PHARMACEUTICALS INC23.39119.063B
REGN REGENERON PHARMACEUTICALS16.7882.713B
ALNY ALNYLAM PHARMACEUTICALS INC50.1944.834B
INSM INSMED INC N/A34.336B
NTRA NATERA INC N/A30.104B
BIIB BIOGEN INC12.6228.19B
UTHR UNITED THERAPEUTICS CORP16.0620.691B

Related stock screener links

View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges

About EVAX

Company Profile

EVAX logo image Evaxion AS engages in the discovery and development of immunotherapies for cancer and infectious diseases. The firm decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.

Company Info

EVAXION A/S

Dr. Neergaards Vej 5F

Hoersholm 1260 DK

CEO: Lars Staal Webner

Employees: 46

EVAX Company Website

EVAX Investor Relations

EVAXION A/S / EVAX FAQ

Can you describe the business of EVAXION A/S?

Evaxion AS engages in the discovery and development of immunotherapies for cancer and infectious diseases. The firm decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.


Can you provide the latest stock price for EVAXION A/S?

The current stock price of EVAX is 3.29 USD. The price decreased by -5.46% in the last trading session.


Does EVAXION A/S pay dividends?

EVAX does not pay a dividend.


How is the ChartMill rating for EVAXION A/S?

EVAX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


How is the valuation of EVAXION A/S (EVAX) based on its PE ratio?

EVAXION A/S (EVAX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.01).


What is the expected growth for EVAX stock?

The Revenue of EVAXION A/S (EVAX) is expected to grow by 14.66% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.


What is EVAXION A/S worth?

EVAXION A/S (EVAX) has a market capitalization of 27.44M USD. This makes EVAX a Nano Cap stock.